Are new weight loss drugs an answer or problem?
World of DTC Marketing
JULY 17, 2022
Novo Nordisk more than doubled its sales targets for obesity drugs to $3.7bn by 2025. But before the company can make Wegovy mainstream, it has to convince doctors to prescribe it and insurers and governments to pay for it. Even if Novo Nordisk can win doctors over, it faces a more significant challenge in convincing reluctant payers.
Let's personalize your content